<DOC>
	<DOCNO>NCT00962104</DOCNO>
	<brief_summary>The purpose study ass efficacy , quality life , safety multiple dose atomoxetine Asian adult subject attention deficit/hyperactivity disorder ( ADHD ) .</brief_summary>
	<brief_title>Atomoxetine Treat Asian Adult Patients With Attention-Deficit/Hyperactivity Disorder</brief_title>
	<detailed_description>The treatment initiated low dosage 40 milligram per day ( mg/day ) , titrate 80 mg/day . Patients unable tolerate dose least 80 mg/day end study discontinue . The dosage titrate maximum 120 mg/day .</detailed_description>
	<mesh_term>Disease</mesh_term>
	<mesh_term>Attention Deficit Disorder Hyperactivity</mesh_term>
	<mesh_term>Hyperkinesis</mesh_term>
	<mesh_term>Atomoxetine Hydrochloride</mesh_term>
	<criteria>Patients must meet Diagnostic Statistical Manual Mental Disorders , Fourth Edition , Text Revision ( DSMIVTR ) criteria current attention deficit/hyperactivity disorder ( ADHD ) well criteria historical diagnosis ADHD childhood , assess Conners ' Adult AttentionDeficit/Hyperactivity Disorder Diagnostic Interview Diagnostic Statistical Manual Mental Disorders , Fourth Edition screen Patients must score 2 great least 6 item either inattentive hyperactive/impulsive core subscales randomization screen rat Conners ' Adult AttentionDeficit/Hyperactivity Disorder Rating ScaleInvestigator Rated : Screening Version ( CAARSInv : SV ) 18item total ADHD symptom score . In addition , total score 18item total ADHD symptom score must 20 great . Patients must Clinical Global ImpressionsAttentionDeficit/Hyperactivity DisorderSeverity score 4 ( moderate symptom ) great . Patients must judge investigator reliable keep appointment clinic visit test , require protocol . Patients must possess educational level degree understanding language country enable communicate suitably investigator study coordinator . Patients must able swallow capsule . Patients meet full DSMIVTR diagnostic criterion history bipolar disorder history schizophrenia psychotic disorder , patient receive injectable sustainedrelease neuroleptic . Patients depressive disorder also total score 12 great Hamilton Depression Rating Scale17 item randomization . Patients current past history major depression receive antidepression drug therapy within 6 month screen . Patients meet DSMIVTR diagnostic criterion current anxiety disorder also patient require antianxiety drug therapy , except take benzodiazepine analog anxiety , need limit . Patients diagnose ( DSMIVTR ) pervasive developmental disorder . Patients , opinion investigator , serious suicidal risk serious risk harm others , whose score Item 11 Hamilton Depression Rating Scale17 item equal 2 randomization screening . Patients receive atomoxetine prior clinical study . Patients significant medical condition likely become unstable trial would likely destabilize treatment atomoxetine . Patients history allergy atomoxetine , severe allergy 1 class medication , multiple adverse drug reaction . Patients receive treatment within past 30 day drug receive regulatory approval indication time inform consent document obtain .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2012</verification_date>
	<keyword>ADHD</keyword>
</DOC>